AFP and cholangiocarcinoma: Levels of AFP-L3%, PIVKA-II, GALAD, ASAP, GALAD-C, GAAP, C-GALAD, C-GALAD II, AFP and GAP-TALAD in HCC patients were significantly (p < 0.05) higher than those in non-HCC (CCA and benign liver diseases) patients (Table 2).